Clinical Trial

Efficacy and Safety of PCSK9 Inhibitors in Patients With Large-Artery Atherosclerosis (LAA) Ischemic Stroke

Recruiting
View on ClinicalTrials.gov →
Summary
This prospective multicenter cohort study aims to evaluate the effectiveness and safety of early PCSK9 inhibitor therapy in patients with large-artery atherosclerotic ischemic stroke. The study will compare early neurological improvement, lipid-lowering effect, 90-day functional outcome, recurrent cardio-cerebrovascular events, and safety outcomes between patients treated with evolocumab plus statin and those treated with statin alone.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-04-13.
Trial Details
NCT Number NCT07540741
Lead Sponsor First Affiliated Hospital of Harbin Medical University
Conditions Acute Ischemic Stroke
Enrollment 1,000 participants
Start Date 2025-12-03
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-23